Physician profile
Olga Joukovski
NPI 1437256179
$5,444.23
in general payments reported to CMS, 2019-2025
22 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $301 · 2021: $736 · 2022: $518 · 2023: $308 · 2024: $1,326 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,810.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,016.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $726.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $355.67 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $317.04 | 2024-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $292.45 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Medtronic USA, INC. | $156.27 | 2019 | |
| Pfizer INC. | $155.15 | 2023-2025 | |
| Angiodynamics, INC. | $140.42 | 2022 | |
| Axsome Therapeutics, INC. | $121.45 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $83.04 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $68.03 | 2024-2025 | |
| Phadia US INC. | $46.25 | 2025 | Immunocap |
| Abbott Laboratories | $23.91 | 2024 | Freestyle Libre 3 |
| Shield Therapeutics INC | $20.75 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $19.80 | 2024 | |
| Exact Sciences Corporation | $17.08 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $15.83 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $15.78 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $15.26 | 2025 | Arexvy, Shingrix |
| Scilex Pharmaceuticals INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Joukovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.